These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 25342117

  • 1. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
    Kanters TA, Redekop WK, Kruijshaar ME, van der Ploeg AT, Rutten-van Mölken MP, Hakkaart L.
    Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
    [Abstract] [Full Text] [Related]

  • 2. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N, Boonen A, van den Bergh JP, van Kuijk SMJ, Wyers CE, van Oostwaard M, Vranken L, Bours SPG, Hiligsmann M.
    J Med Econ; 2022 Apr; 25(1):829-839. PubMed ID: 35674412
    [Abstract] [Full Text] [Related]

  • 3. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F, Carotti M, Ciapetti A, Gasparini S, Grassi W.
    Clin Exp Rheumatol; 2011 Apr; 29(4):661-71. PubMed ID: 21813061
    [Abstract] [Full Text] [Related]

  • 4. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
    Selva-Sevilla C, Ferrara P, Gerónimo-Pardo M.
    Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
    [Abstract] [Full Text] [Related]

  • 5. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
    Gerhards SA, Huibers MJ, Theunissen KA, de Graaf LE, Widdershoven GA, Evers SM.
    Value Health; 2011 Jun; 14(5):732-9. PubMed ID: 21839412
    [Abstract] [Full Text] [Related]

  • 6. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?
    Boonen A, van der Heijde D, Landewé R, van Tubergen A, Mielants H, Dougados M, van der Linden S.
    Ann Rheum Dis; 2007 Jun; 66(6):771-7. PubMed ID: 17213254
    [Abstract] [Full Text] [Related]

  • 7. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
    Dritsaki M, Petrou S, Williams M, Lamb SE.
    Health Qual Life Outcomes; 2017 Jan 24; 15(1):20. PubMed ID: 28118833
    [Abstract] [Full Text] [Related]

  • 8. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients.
    Wu J, Han Y, Zhao FL, Zhou J, Chen Z, Sun H.
    Health Qual Life Outcomes; 2014 Oct 25; 12():156. PubMed ID: 25343944
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the EQ-5D and the SF-6D utility measures in 813 patients with early arthritis: results from the ESPOIR cohort.
    Gaujoux-Viala C, Rat AC, Guillemin F, Flipo RM, Fardellone P, Bourgeois P, Fautrel B.
    J Rheumatol; 2011 Aug 25; 38(8):1576-84. PubMed ID: 21532054
    [Abstract] [Full Text] [Related]

  • 10. VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSON´S DISEASE POPULATION SAMPLE.
    Garcia-Gordillo MÁ, Del Pozo-Cruz B, Adsuar JC, Cordero-Ferrera JM, Abellan-Perpiñan JM, Sanchez-Martinez FI.
    Nutr Hosp; 2015 Dec 01; 32(6):2808-21. PubMed ID: 26667738
    [Abstract] [Full Text] [Related]

  • 11. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD).
    Chen J, Wong CK, McGhee SM, Pang PK, Yu WC.
    PLoS One; 2014 Dec 01; 9(11):e112389. PubMed ID: 25379673
    [Abstract] [Full Text] [Related]

  • 12. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
    Kontodimopoulos N, Stamatopoulou E, Brinia A, Talias MA, Ferreira LN.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec 01; 18(6):667-675. PubMed ID: 30048194
    [Abstract] [Full Text] [Related]

  • 13. A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
    Kangwanrattanakul K.
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug 01; 21(4):765-774. PubMed ID: 32981380
    [Abstract] [Full Text] [Related]

  • 14. Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.
    Lamu AN, Björkman L, Hamre HJ, Alræk T, Musial F, Robberstad B.
    Health Qual Life Outcomes; 2021 Apr 17; 19(1):125. PubMed ID: 33865400
    [Abstract] [Full Text] [Related]

  • 15. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
    Gandhi M, Ang M, Teo K, Wong CW, Wei YC, Tan RL, Janssen MF, Luo N.
    Patient; 2019 Aug 17; 12(4):383-392. PubMed ID: 30607809
    [Abstract] [Full Text] [Related]

  • 16. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
    Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC.
    Value Health; 2010 Aug 17; 13(5):649-56. PubMed ID: 20412540
    [Abstract] [Full Text] [Related]

  • 17. A review of the psychometric properties of generic utility measures in multiple sclerosis.
    Kuspinar A, Mayo NE.
    Pharmacoeconomics; 2014 Aug 17; 32(8):759-73. PubMed ID: 24846760
    [Abstract] [Full Text] [Related]

  • 18. Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis.
    Tawiah AK, Al Sayah F, Ohinmaa A, Johnson JA.
    Health Qual Life Outcomes; 2019 Apr 17; 17(1):68. PubMed ID: 30995930
    [Abstract] [Full Text] [Related]

  • 19. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
    Kontodimopoulos N, Argiriou M, Theakos N, Niakas D.
    Eur J Health Econ; 2011 Aug 17; 12(4):383-91. PubMed ID: 20473544
    [Abstract] [Full Text] [Related]

  • 20. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
    Tramontano AC, Schrag DL, Malin JK, Miller MC, Weeks JC, Swan JS, McMahon PM.
    Med Decis Making; 2015 Apr 17; 35(3):371-87. PubMed ID: 25670839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.